96 related articles for article (PubMed ID: 8698456)
21. Interspecies communication among commensal and pathogenic streptococci.
Cook LC; LaSarre B; Federle MJ
mBio; 2013 Jul; 4(4):. PubMed ID: 23882015
[TBL] [Abstract][Full Text] [Related]
22. Protease-dependent mechanisms of complement evasion by bacterial pathogens.
Potempa M; Potempa J
Biol Chem; 2012 Sep; 393(9):873-88. PubMed ID: 22944688
[TBL] [Abstract][Full Text] [Related]
23. Vaccination against rheumatic heart disease: a review of current research strategies and challenges.
Pandey M; Batzloff MR; Good MF
Curr Infect Dis Rep; 2012 Aug; 14(4):381-90. PubMed ID: 22729401
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model.
Santillan DA; Rai KK; Santillan MK; Krishnamachari Y; Salem AK; Hunter SK
Am J Obstet Gynecol; 2011 Sep; 205(3):249.e1-8. PubMed ID: 21802065
[TBL] [Abstract][Full Text] [Related]
25. Emergence and global dissemination of host-specific Streptococcus agalactiae clones.
Sørensen UB; Poulsen K; Ghezzo C; Margarit I; Kilian M
mBio; 2010 Aug; 1(3):. PubMed ID: 20824105
[TBL] [Abstract][Full Text] [Related]
26. Streptococcus adherence and colonization.
Nobbs AH; Lamont RJ; Jenkinson HF
Microbiol Mol Biol Rev; 2009 Sep; 73(3):407-50, Table of Contents. PubMed ID: 19721085
[TBL] [Abstract][Full Text] [Related]
27. Putative novel surface-exposed Streptococcus agalactiae protein frequently expressed by the group B streptococcus from Zimbabwe.
Mavenyengwa RT; Maeland JA; Moyo SR
Clin Vaccine Immunol; 2009 Sep; 16(9):1302-8. PubMed ID: 19587152
[TBL] [Abstract][Full Text] [Related]
28. Human serum induces streptococcal c5a peptidase expression.
Gleich-Theurer U; Aymanns S; Haas G; Mauerer S; Vogt J; Spellerberg B
Infect Immun; 2009 Sep; 77(9):3817-25. PubMed ID: 19506013
[TBL] [Abstract][Full Text] [Related]
29. Complement evasion by human pathogens.
Lambris JD; Ricklin D; Geisbrecht BV
Nat Rev Microbiol; 2008 Feb; 6(2):132-42. PubMed ID: 18197169
[TBL] [Abstract][Full Text] [Related]
30. Group B Streptococcus: global incidence and vaccine development.
Johri AK; Paoletti LC; Glaser P; Dua M; Sharma PK; Grandi G; Rappuoli R
Nat Rev Microbiol; 2006 Dec; 4(12):932-42. PubMed ID: 17088932
[TBL] [Abstract][Full Text] [Related]
31. High-affinity interaction between fibronectin and the group B streptococcal C5a peptidase is unaffected by a naturally occurring four-amino-acid deletion that eliminates peptidase activity.
Tamura GS; Hull JR; Oberg MD; Castner DG
Infect Immun; 2006 Oct; 74(10):5739-46. PubMed ID: 16988251
[TBL] [Abstract][Full Text] [Related]
32. Abundance of the delta subunit of RNA polymerase is linked to the virulence of Streptococcus agalactiae.
Seepersaud R; Needham RH; Kim CS; Jones AL
J Bacteriol; 2006 Mar; 188(6):2096-105. PubMed ID: 16513739
[TBL] [Abstract][Full Text] [Related]
33. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.
Park HS; Cleary PP
Infect Immun; 2005 Dec; 73(12):7878-86. PubMed ID: 16299278
[TBL] [Abstract][Full Text] [Related]
34. The SrtA Sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine.
Lalioui L; Pellegrini E; Dramsi S; Baptista M; Bourgeois N; Doucet-Populaire F; Rusniok C; Zouine M; Glaser P; Kunst F; Poyart C; Trieu-Cuot P
Infect Immun; 2005 Jun; 73(6):3342-50. PubMed ID: 15908360
[TBL] [Abstract][Full Text] [Related]
35. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.
Lindahl G; Stålhammar-Carlemalm M; Areschoug T
Clin Microbiol Rev; 2005 Jan; 18(1):102-27. PubMed ID: 15653821
[TBL] [Abstract][Full Text] [Related]
36. Molecular epidemiology of group B streptococcal infections.
Tkacikova E; Mikula I; Dmitriev A
Folia Microbiol (Praha); 2004; 49(4):387-97. PubMed ID: 15530003
[TBL] [Abstract][Full Text] [Related]
37. Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes.
Collin M; Olsén A
Infect Immun; 2003 Jun; 71(6):2983-92. PubMed ID: 12761074
[No Abstract] [Full Text] [Related]
38. A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen.
Harris TO; Shelver DW; Bohnsack JF; Rubens CE
J Clin Invest; 2003 Jan; 111(1):61-70. PubMed ID: 12511589
[TBL] [Abstract][Full Text] [Related]
39. Structural heterogeneity of the streptococcal C5a peptidase gene in Streptococcus pyogenes.
Koroleva IV; Efstratiou A; Suvorov AN
J Bacteriol; 2002 Nov; 184(22):6384-6. PubMed ID: 12399509
[TBL] [Abstract][Full Text] [Related]
40. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.
Cheng Q; Debol S; Lam H; Eby R; Edwards L; Matsuka Y; Olmsted SB; Cleary PP
Infect Immun; 2002 Nov; 70(11):6409-15. PubMed ID: 12379721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
